DelistingJun 12, 2026, 05:02 PM
XORTX Therapeutics to Voluntarily Delist Common Shares from TSXV
AI Summary
XORTX Therapeutics Inc. announced its decision to voluntarily delist its common shares from the TSX Venture Exchange (TSXV). This strategic move aims to eliminate duplicative exchange fees, reduce legal and accounting expenses, optimize financing, and minimize regulatory complexity, allowing greater management focus on its XRx-026 program for gout. Shareholders will maintain full trading access on Nasdaq, and no action is required from them. The delisting was approved by the Board of Directors and does not require shareholder approval as shares are listed on an acceptable alternative market.
Key Highlights
- XORTX Therapeutics will voluntarily delist its common shares from the TSX Venture Exchange (TSXV).
- The decision was made after a comprehensive evaluation, citing high costs and administrative requirements of dual listing.
- The delisting is expected to eliminate duplicative exchange fees and reduce legal and accounting expenses.
- It aims to optimize company financing initiatives and minimize regulatory complexity.
- The move will enable greater management focus on the XRx-026 program for the treatment of gout.
- All shareholders, including Canadian shareholders, will maintain full trading access on Nasdaq.
- The voluntary delisting was approved by the Company's Board of Directors and does not require shareholder approval.
Price Impact
More from XRTX